Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine > Partnership > EAU - European Association of Urology > Early detection of prostate cancer

Early detection of prostate cancer

  • 22 October 2020
  • External Contributor
European Association of Urology
Total
0
Shares
0
0
0
0
0

Europe’s chance to save lives and increase quality of life for prostate cancer patients

For a number of years now, the European Association of Urology has been working with patient cancer organisations to raise the profile of prostate cancer in EU policies and activities. With the EU Cancer Plan, the European Commission has a unique opportunity to take forward the fight against prostate cancer and to build consensus, so that together, we can beat this disease.

Why is prostate cancer an important condition for the EU to address? Well, first and foremost, prostate cancer is a serious European public health issue that has a significant impact on patients and their families, and on health systems across Europe. Prostate cancer is the most common male cancer, and killed 107,000 men in Europe in 2018; it is thus not an indolent disease. It is responsible for 10% of all male cancer deaths and is the second cause of male cancer death before colorectal cancer. Today, prostate cancer kills more men than breast cancer kills women.

Despite this significant public health burden, relatively little is performed at EU level on prostate cancer, particularly in comparison to breast, cervical and colorectal cancers, which have all benefited from technical guidelines from the European Commission on early detection (on the basis of a mandate from the European Council Recommendations in 2003 on cancer screening).

Earlier in 2020, in order to respond to the consultation on the EU Cancer Plan, we joined forces with Movember, Europa Uomo, the European Cancer Patient Coalition and the European Alliance of Personalised Medicine to update our 2017 White Paper on Prostate Cancer. This updated White Paper gives recommendations on how the EU Cancer Plan can tackle prostate cancer.

One clear recommendation from the White Paper is to add prostate cancer to the list of cancers that benefit from European Commission supported guidelines on early detection. The evidence is clear: early detection of prostate cancer in well- informed men saves lives, improves quality of life and reduces costs for health care systems. We would like the EU Cancer Plan to tackle EU wide guidance on this, as it has done with other cancers in the past.

The early detection of prostate cancer has been controversial because the use of PSA testing (that is the test that measures the amount of prostate specific antigen (PSA) in the blood to estimate the risk of prostate cancer in men) has led to a drop in mortality rates, but has come at the cost of over-diagnosis and overtreatment.

The most updated scientific evidence supports the use of PSA in early detection of prostate cancer with a risk-adapted approach in informed men, thus avoiding over-diagnosis and overtreatment. PSA can now be used more cleverly with Magnetic Resonance Imaging (MRI) and further risk stratification (using risk calculators which are freely available on the web) in men at higher risk. This combined approach will allow a substantial reduction of over-diagnosis and the number of men who need to undergo biopsy. Also, with the application of MRI- guided active surveillance for all low- and some intermediate- risk prostate cancers, the monitoring of patients can happen less invasively. This approach is reflected in the multidisciplinary ‘EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer’ https://uroweb.org/guideline/prostate-cancer/.

The EU Cancer Plan offers the European Commission a unique opportunity to tackle this issue and support EU member states to deliver consistent and clear guidelines on early detection of prostate cancer. By doing this, it can save lives and increase quality of life outcomes for patients across Europe.

We invite anyone interested in this subject to join us on 17 November at 17h30 for a virtual event on prostate cancer in the EU Cancer Plan, focusing on early detection. For more registration and more information on the event and the prostate cancer campaign, please see epad.uroweb.org.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
External Contributor

You May Also Like
View Post
  • Obituaries

Hansjörg Senn of St Gallen: A practice-changing career

  • Anna Wagstaff
  • 3 February 2023
View Post
  • News

Study highlights need to reanalyse genomics and genetics of metastatic tumours

  • Janet Fricker
  • 27 January 2023
View Post
  • Articles
  • Policy

The cancer patients still struggling to access drugs in the wake of anti-corruption reforms

  • Giselle Vidal
  • 27 January 2023
View Post
  • Supported contents

AI in Genomics and Reporting for Clinical Practice

  • Adriana Albini
  • 26 January 2023
View Post
  • News

Current cervical cancer screening paradigm fails older women

  • Janet Fricker
  • 26 January 2023
View Post
  • Articles
  • Delivery of Care

Immunotherapy: outcomes of ultra low-dose trial offer hope for better global access

  • Swagata Yadavar
  • 26 January 2023
View Post
  • Supported contents

Telemedicine in Cancer Care: Monitoring, Follow-Up,Tele-Rehabilitation, Palliative and Supportive Care

  • Adriana Albini
  • 23 January 2023
View Post
  • Articles
  • Policy

Cervical cancer elimination efforts boosted by simpler ways to identify and treat pre-cancerous lesions

  • Esther Nakkazi
  • 12 January 2023
search
or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Study highlights need to reanalyse genomics and genetics of metastatic tumours
    • 27 January 2023
  • Current cervical cancer screening paradigm fails older women
    • 26 January 2023
  • Call-to-arms for Europe to provide essential paediatric anti-cancer medicines
    • 9 January 2023
  • Exercise-stimulated myokine production can extend survival in advanced prostate cancer
    • 9 January 2023
  • Five San Antonio take-aways to improve care of breast cancer patients
    • 16 December 2022
Article
  • The cancer patients still struggling to access drugs in the wake of anti-corruption reforms
    • 27 January 2023
  • Immunotherapy: outcomes of ultra low-dose trial offer hope for better global access
    • 26 January 2023
  • Cervical cancer elimination efforts boosted by simpler ways to identify and treat pre-cancerous lesions
    • 12 January 2023
Latest printed issue
Social

Would you follow us ?

Contents
  • Hansjörg Senn of St Gallen: A practice-changing career
    • 3 February 2023
  • AI in Genomics and Reporting for Clinical Practice
    • 26 January 2023
  • Telemedicine in Cancer Care: Monitoring, Follow-Up,Tele-Rehabilitation, Palliative and Supportive Care
    • 23 January 2023
MENU
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine
  • About the Magazine
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is funded by SPCC Sharing Progress in Cancer Care | Via Vincenzo Vela 6, 6500 Bellinzona - Switzerland | info@spcc.net

Archivio Cancerworld

Input your search keywords and press Enter.